Cargando…
Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks
BACKGROUND: Cardiovascular (CV) complications are the most significant cause of mortality in adults with Cushing disease (CD); little is known about CV risk factors in children with CD. Measurement of lipoprotein particles by nuclear magnetic resonance (NMR) spectroscopy is a novel technology to ass...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702083/ https://www.ncbi.nlm.nih.gov/pubmed/31112990 http://dx.doi.org/10.1038/s41390-019-0438-0 |
_version_ | 1783445156349870080 |
---|---|
author | Makri, Angeliki Cheung, Anita Sinaii, Ninet Remaley, Alan T. Sampson, Maureen Keil, Meg Belyavskaya, Elena Lyssikatos, Charalampos De La Luz Sierra, Maria Stratakis, Constantine A. Lodish, Maya |
author_facet | Makri, Angeliki Cheung, Anita Sinaii, Ninet Remaley, Alan T. Sampson, Maureen Keil, Meg Belyavskaya, Elena Lyssikatos, Charalampos De La Luz Sierra, Maria Stratakis, Constantine A. Lodish, Maya |
author_sort | Makri, Angeliki |
collection | PubMed |
description | BACKGROUND: Cardiovascular (CV) complications are the most significant cause of mortality in adults with Cushing disease (CD); little is known about CV risk factors in children with CD. Measurement of lipoprotein particles by nuclear magnetic resonance (NMR) spectroscopy is a novel technology to assess CV risk. The objective of the current study is to analyze the NMR lipid profile in pediatric CD patients before and 1 year after remission. METHODS: NMR lipid profile was obtained via the Vantera NMR analyzer, using frozen serum samples from 33 CD patients (mean age 13.8 ± 4.0 years) evaluated between 1997 and 2017 at the National Institutes of Health (NIH) Clinical Center (CC). RESULTS: GlycA, triglyceride-rich particles (TRLP medium and very small sizes), LDL particles (LDLP total and large size), HDL particles (HDLP total, medium and small sizes), total cholesterol, LDL cholesterol, HDL cholesterol, GlycA inflammatory biomarker, Apolipoprotein B and Apolipoprotein A1 concentrations showed statistically significant changes after remission of CD (p<0.05). CONCLUSION: In our study population, most of the lipid variables improved post-CDremission, with the exception of HDL and apoA1, indicating that NMR lipoprotein profile may be a helpful tool in assessing the cardiovascular risk in pediatric patients with CD. |
format | Online Article Text |
id | pubmed-6702083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-67020832019-11-21 Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks Makri, Angeliki Cheung, Anita Sinaii, Ninet Remaley, Alan T. Sampson, Maureen Keil, Meg Belyavskaya, Elena Lyssikatos, Charalampos De La Luz Sierra, Maria Stratakis, Constantine A. Lodish, Maya Pediatr Res Article BACKGROUND: Cardiovascular (CV) complications are the most significant cause of mortality in adults with Cushing disease (CD); little is known about CV risk factors in children with CD. Measurement of lipoprotein particles by nuclear magnetic resonance (NMR) spectroscopy is a novel technology to assess CV risk. The objective of the current study is to analyze the NMR lipid profile in pediatric CD patients before and 1 year after remission. METHODS: NMR lipid profile was obtained via the Vantera NMR analyzer, using frozen serum samples from 33 CD patients (mean age 13.8 ± 4.0 years) evaluated between 1997 and 2017 at the National Institutes of Health (NIH) Clinical Center (CC). RESULTS: GlycA, triglyceride-rich particles (TRLP medium and very small sizes), LDL particles (LDLP total and large size), HDL particles (HDLP total, medium and small sizes), total cholesterol, LDL cholesterol, HDL cholesterol, GlycA inflammatory biomarker, Apolipoprotein B and Apolipoprotein A1 concentrations showed statistically significant changes after remission of CD (p<0.05). CONCLUSION: In our study population, most of the lipid variables improved post-CDremission, with the exception of HDL and apoA1, indicating that NMR lipoprotein profile may be a helpful tool in assessing the cardiovascular risk in pediatric patients with CD. 2019-05-21 2019-09 /pmc/articles/PMC6702083/ /pubmed/31112990 http://dx.doi.org/10.1038/s41390-019-0438-0 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Makri, Angeliki Cheung, Anita Sinaii, Ninet Remaley, Alan T. Sampson, Maureen Keil, Meg Belyavskaya, Elena Lyssikatos, Charalampos De La Luz Sierra, Maria Stratakis, Constantine A. Lodish, Maya Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks |
title | Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks |
title_full | Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks |
title_fullStr | Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks |
title_full_unstemmed | Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks |
title_short | Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks |
title_sort | lipoprotein particles in patients with pediatric cushing disease and possible cardiovascular risks |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702083/ https://www.ncbi.nlm.nih.gov/pubmed/31112990 http://dx.doi.org/10.1038/s41390-019-0438-0 |
work_keys_str_mv | AT makriangeliki lipoproteinparticlesinpatientswithpediatriccushingdiseaseandpossiblecardiovascularrisks AT cheunganita lipoproteinparticlesinpatientswithpediatriccushingdiseaseandpossiblecardiovascularrisks AT sinaiininet lipoproteinparticlesinpatientswithpediatriccushingdiseaseandpossiblecardiovascularrisks AT remaleyalant lipoproteinparticlesinpatientswithpediatriccushingdiseaseandpossiblecardiovascularrisks AT sampsonmaureen lipoproteinparticlesinpatientswithpediatriccushingdiseaseandpossiblecardiovascularrisks AT keilmeg lipoproteinparticlesinpatientswithpediatriccushingdiseaseandpossiblecardiovascularrisks AT belyavskayaelena lipoproteinparticlesinpatientswithpediatriccushingdiseaseandpossiblecardiovascularrisks AT lyssikatoscharalampos lipoproteinparticlesinpatientswithpediatriccushingdiseaseandpossiblecardiovascularrisks AT delaluzsierramaria lipoproteinparticlesinpatientswithpediatriccushingdiseaseandpossiblecardiovascularrisks AT stratakisconstantinea lipoproteinparticlesinpatientswithpediatriccushingdiseaseandpossiblecardiovascularrisks AT lodishmaya lipoproteinparticlesinpatientswithpediatriccushingdiseaseandpossiblecardiovascularrisks |